Scientists at Stanford Medicine have identified a naturally occurring molecule that appears to mimic some of the weight loss effects of semaglutide, the drug widely known as Ozempic. In animal studies, the molecule reduced appetite and body weight while avoiding several common side effects such as nausea, constipation, and muscle loss. This groundbreaking discovery, detailed in the prestigious journal Nature, could herald a new era in obesity treatment, offering a more targeted and potentially better-tolerated approach to metabolic health.
The newly identified molecule, dubbed BRP (BRINP2-related-peptide), operates through a distinct yet related biological pathway to semaglutide. Unlike semaglutide, which interacts with receptors throughout the body, including the gut and pancreas, BRP appears to exert its effects specifically within the hypothalamus, the brain region critically responsible for regulating appetite and metabolism. This targeted action suggests BRP may offer a more precise mechanism for controlling food intake and energy balance, potentially bypassing the systemic side effects associated with broader-acting drugs.
"The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas and other tissues," explained Dr. Katrin Svensson, assistant professor of pathology at Stanford Medicine and senior author of the study. "That’s why Ozempic has widespread effects including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism."
This precision is a key differentiator, as it could translate to a significantly improved patient experience. The widespread adoption of semaglutide for weight loss has been tempered by a significant proportion of users experiencing gastrointestinal distress, including nausea, vomiting, diarrhea, and constipation. Furthermore, unintended muscle loss has been a concern with rapid weight reduction, a side effect that BRP’s targeted action may help mitigate.
The journey to discovering BRP was a testament to the power of artificial intelligence in scientific research. The Stanford team leveraged AI to navigate the complex landscape of prohormones, a class of precursor molecules that can be cleaved into smaller, biologically active peptides. Traditional methods for identifying these signaling peptides are laborious and often inefficient, making the discovery of rare, potent molecules a significant challenge.
The AI-Driven Hunt for Novel Peptides
The discovery process began with the meticulous analysis of prohormones, large inactive molecules that, when processed, yield smaller peptide hormones. These peptides play crucial roles in regulating a myriad of bodily functions, including metabolism, appetite, and mood. However, the sheer number of potential cleavage sites within each prohormone, coupled with the vastness of the human genome, presented an immense hurdle for conventional research methods. Identifying the specific peptide fragments that act as key signaling molecules from the myriad of inactive byproducts of protein breakdown is akin to finding a needle in a haystack.
To overcome this challenge, researchers focused on a specific enzyme, prohormone convertase 1/3 (PC1/3). This enzyme is known to cleave proteins at particular locations and has been implicated in obesity. A well-established product of PC1/3 activity is glucagon-like peptide-1 (GLP-1), the target mimicked by semaglutide and other GLP-1 receptor agonists. By understanding the enzymatic machinery involved in generating appetite-regulating peptides, the team aimed to uncover other, potentially novel, molecules produced by similar processes.
The breakthrough came with the development of a sophisticated computational tool, aptly named "Peptide Predictor." This AI algorithm systematically scanned all 20,000 human protein-coding genes. Its task was to identify prohormones that could be cleaved by PC1/3 into potentially active peptides. The algorithm was designed to prioritize proteins that are secreted outside of cells, a characteristic of signaling hormones, and those possessing multiple cleavage sites that could yield a diverse array of peptides. This intelligent filtering process narrowed down the vast genomic data to a more manageable list of 373 candidate prohormones.
"The algorithm was absolutely key to our findings," Dr. Svensson emphasized, highlighting the transformative role of AI in accelerating scientific discovery.
From these 373 prohormones, the Peptide Predictor generated a list of 2,683 potential peptides. The research team then embarked on the next phase: experimental validation. They selected 100 of these predicted peptides, including GLP-1 as a benchmark, for testing on lab-grown brain cells.
BRP Emerges: A Tiny Peptide with Potent Effects
The in-vitro experiments yielded compelling results. As anticipated, GLP-1 demonstrated its known ability to increase neuronal activity. However, one particular peptide, significantly smaller than GLP-1 and composed of only 12 amino acids, produced a remarkable tenfold increase in neuronal activity compared to the control group. This potent peptide was subsequently named BRP, derived from its parent molecule, BPM/retinoic acid inducible neural specific 2, or BRINP2.
The initial success in cell cultures spurred further investigation in more complex animal models. The researchers proceeded to conduct studies using both lean mice and minipigs. Minipigs were chosen deliberately due to their physiological similarities to humans, particularly in their metabolic processes and eating patterns, making them a more accurate preclinical model than mice alone.
Preclinical Data: Significant Appetite Reduction and Fat Loss
The results from these animal studies were highly encouraging. A single injection of BRP administered before feeding in both lean mice and minipigs led to a substantial reduction in food intake, with consumption dropping by up to 50% within an hour. This immediate and significant impact on appetite suggests BRP could be a powerful tool for curbing overeating.
In obese mice, the effects were even more pronounced over a longer period. Daily injections of BRP for 14 days resulted in an average weight loss of 3 grams, predominantly from fat mass. This occurred while a control group of untreated obese mice actually gained approximately 3 grams during the same timeframe, underscoring BRP’s efficacy in promoting weight reduction. Beyond weight loss, the treated animals also exhibited notable improvements in glucose tolerance and insulin sensitivity, key indicators of metabolic health that are often impaired in obesity.
Crucially, these positive outcomes were not accompanied by adverse effects. The animals treated with BRP did not display any changes in their movement patterns, water intake, anxiety-like behaviors, or digestive function. This observation strongly suggests that BRP’s mechanism of action is highly specific, avoiding the systemic disruptions that can accompany broader-acting drugs. Further analyses confirmed that BRP operates through distinct brain and metabolic pathways compared to GLP-1 or semaglutide, reinforcing the hypothesis of a more targeted and potentially safer mode of action.
The Path Forward: Human Trials and Future Implications
The successful preclinical data has paved the way for the next critical stage: human clinical trials. Dr. Svensson, who has co-founded a company dedicated to advancing this research, indicated that human trials are planned for the near future. The immediate focus for the research team is to fully elucidate the specific receptors that BRP interacts with and to gain a deeper understanding of its precise mechanisms of action within the human body. Furthermore, efforts are underway to explore strategies for extending the duration of BRP’s effects, which could lead to more convenient dosing regimens for potential therapeutic use.
"The lack of effective drugs to treat obesity in humans has been a problem for decades," Dr. Svensson stated. "Nothing we’ve tested before has compared to semaglutide’s ability to decrease appetite and body weight. We are very eager to learn if it is safe and effective in humans."
The implications of this discovery are profound. Obesity is a global epidemic, affecting hundreds of millions of people worldwide and contributing to a cascade of serious health complications, including type 2 diabetes, cardiovascular disease, certain cancers, and joint problems. The development of novel, effective, and well-tolerated treatments for obesity remains a critical unmet medical need. If BRP proves to be safe and effective in human trials, it could offer a significant advancement in the fight against this complex disease. Its targeted action could provide a lifeline for individuals who have struggled with weight management due to the side effects of existing therapies or who seek a more precise approach to metabolic control.
The research was a collaborative effort, involving scientists from multiple leading institutions: the University of California, Berkeley; the University of Minnesota; and the University of British Columbia. This multidisciplinary approach underscores the complexity of metabolic research and the benefits of pooling expertise. Funding for this ambitious project was provided by a consortium of prestigious organizations, including the National Institutes of Health (grants R01DK125260, P30DK116074, K99AR081618, and GM113854), various Stanford programs, the American Heart Association, the Carlsberg Foundation, and the Wu Tsai Human Performance Alliance.
Dr. Svensson and Dr. Laetitia Coassolo, the study’s lead author and a senior research scientist, have filed patents related to BRP peptides for the treatment of metabolic disorders. Dr. Svensson’s involvement as a co-founder of Merrifield Therapeutics further signals the commitment to translating this scientific breakthrough into tangible therapeutic solutions for patients. The coming years will be crucial as BRP moves from the laboratory bench to the clinic, holding the promise of a new, targeted approach to managing weight and improving metabolic health for millions globally. The scientific community will be watching closely as human trials commence, eager to see if this naturally occurring molecule can live up to its considerable preclinical potential.
